Denosumab in comparison with different therapies to stop or deal with osteoporosis in people vulnerable to fracture: a scientific evaluation and meta-analysis.
Osteoporos Int. 2016 Sep;27(9):2835-2844
Authors: Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP
UNLABELLED: The intention of this evaluation is to check the efficacy and security of denosumab over different therapies for osteoporosis. The outcomes of this research recommend that the security of denosumab and its efficacy in decreasing fractures will not be considerably completely different from bisphosphonates. Denosumab was, nonetheless, simpler in growing bone mineral density.
INTRODUCTION: This research was carried out to check the efficacy and security of denosumab over different pharmacological therapies for osteoporosis in people vulnerable to fracture.
METHODS: Randomised managed trials evaluating denosumab with one other pharmacological therapy for osteoporosis had been searched in MEDLINE, EMBASE and CENTRAL. Recognized articles had been screened by two impartial reviewers and assessed for inclusion. Information from included research had been extracted and meta-analyses had been carried out utilizing random results fashions.
RESULTS: 9 research together with a complete of 4890 postmenopausal ladies had been recognized. The follow-up interval assorted from 12 to 24 months. In all research besides one, the comparator therapy was a bisphosphonate. There was no statistically important distinction between sufferers receiving denosumab and people receiving a bisphosphonate by way of fracture threat (RR[95 % CI]?=?1.15 [0.84-1.58]), hostile occasions (RR[95 % CI]?=?zero.99 [0.96-1.02]) or deaths (OR[95 % CI]?=?zero.58 [0.12-2.71]). Withdrawals as a result of hostile occasions had been much less frequent in denosumab than in different therapy teams however the distinction didn’t attain statistical significance (OR[95 % CI]?=?zero.68 [0.45-1.04]). The % change in bone mineral density on the complete hip, lumbar backbone, femoral neck and one-third radius was considerably larger in individuals who acquired denosumab (e.g. imply distinction [95 % CI] on the complete hip: 1.06 [0.86-1.25]).
CONCLUSIONS: These outcomes recommend that, after 12 to 24 months, the security and efficacy of denosumab for decreasing fracture threat will not be considerably completely different from bisphosphonates regardless of larger beneficial properties in bone mineral density. In a medical setting, denosumab could show better effectiveness.
PMID: 27120345 [PubMed – indexed for MEDLINE]